

## ASX ANNOUNCEMENT

### Exopharm's LEAP Technology – Further Step Towards US Patent

- The USPTO has issued a 'Notice of Allowance Mailed' note for the Company's LEAP patent application (Application 17/147,033)
- Exopharm's LEAP technology is the only established process for high-scale exosome purification

#### 27 September 2021, Melbourne, Australia:

Exopharm Limited (ASX:EX1), a clinical-stage, global leader in exosome medicines, has made a further step towards a granted US Patent for its LEAP technology.

Exopharm has been alerted to the web site of the United States Patent and Trademark Office (USPTO) about the Company's LEAP patent application and the further progress of that patent application (Application 17/147,033) ('Application') under the United States National Phase. Upon inspection, the USPTO web site shows that the Examiner has upgraded the Application to 'Notice of Allowance Mailed', indicating that the Examiner has accepted recent amendments to the Application, sees the Application as meeting their requirements and is ready to issue the requested patent (subject to some further steps and payment of fees). **At this point a USPTO patent number has not been issued in relation to the Application and there are some formalities that need to be completed.**

Normally the US Patent would be issued around 8 weeks after the marked publication date (date which has not yet been set) and the payment of a fee by the Company to the USPTO. Upon publication the Application is open to objections by other parties.

Normally the Company would make an announcement – giving patent number, the expiry date and its importance - upon the final grant of a patent, immediately upon completion. However, the Company wanted to ensure that this information was broadly available.

Dr Ian Dixon, founder and CEO of Exopharm and a co-inventor of the LEAP technology said, "We have been working steadily and carefully to secure a US Patent for LEAP – a technology we think could become the global standard for purifying exosome medicines." He added "The Notice of Allowance is a good and positive sign of progress towards that goal, but there are some further steps before we get there."

*By the Managing Director - this announcement has been authorised for release by Managing Director.*

### ***Company and Media Enquiries:***

*Join our mailing list to receive updates:*

<http://exo.ph/ExoMails>

[www.exopharm.com](http://www.exopharm.com)

P: +61 (0)3 9111 0026

Rudi Michelson

Monsoon Communications

Tel: +61 (0)3 9620 3333

### **ABOUT EXOPHARM**

Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines funded with near-term revenue generated via partnerships and technology licensing.

As nature's delivery platform for DNA, RNA, and proteins, exosomes are highly-differentiated from synthetic drug delivery systems such as lipid nanoparticles (LNPs). The drug delivery industry is growing at an annual growth rate (CAGR) of 5% and currently valued at around US\$175 billion.

Exosomes are an alternative means of drug delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell penetrating peptides, viral vectors and liposomes. In some uses, exosomes have superiority, including delivering DNA and other medicines into the nucleus of the cell, as is required for the rapidly advancing gene therapy market.

Exopharm's LEAP technology solves the challenge of purifying clinical-grade exosomes at large scale and low cost.

Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.

Exopharm uses variations and combinations of LOAD and EVPS to enable its Biopharma partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems including neurological disease, infectious disease, cancer, and fibrosis.

### **FORWARD LOOKING STATEMENTS**

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current

corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.